TY - JOUR
T1 - Progression of cerebral amyloid angiopathy
T2 - a pathophysiological framework
AU - Koemans, Emma A.
AU - Chhatwal, Jasmeer P.
AU - van Veluw, Susanne J.
AU - van Etten, Ellis S.
AU - van Osch, Matthias J. P.
AU - van Walderveen, Marianne A. A.
AU - Sohrabi, Hamid R.
AU - Kozberg, Mariel G.
AU - Shirzadi, Zahra
AU - Terwindt, Gisela M.
AU - van Buchem, Mark A.
AU - Smith, Eric E.
AU - Werring, David J.
AU - Martins, Ralph N.
AU - Wermer, Marieke J. H.
AU - Greenberg, Steven M.
PY - 2023/7
Y1 - 2023/7
N2 - Cerebral amyloid angiopathy, which is defined by cerebrovascular deposition of amyloid β, is a common age-related small vessel pathology associated with intracerebral haemorrhage and cognitive impairment. Based on complementary lines of evidence from in vivo studies of individuals with hereditary, sporadic, and iatrogenic forms of cerebral amyloid angiopathy, histopathological analyses of affected brains, and experimental studies in transgenic mouse models, we present a framework and timeline for the progression of cerebral amyloid angiopathy from subclinical pathology to the clinical manifestation of the disease. Key stages that appear to evolve sequentially over two to three decades are (stage one) initial vascular amyloid deposition, (stage two) alteration of cerebrovascular physiology, (stage three) non-haemorrhagic brain injury, and (stage four) appearance of haemorrhagic brain lesions. This timeline of stages and the mechanistic processes that link them have substantial implications for identifying disease-modifying interventions for cerebral amyloid angiopathy and potentially for other cerebral small vessel diseases.
AB - Cerebral amyloid angiopathy, which is defined by cerebrovascular deposition of amyloid β, is a common age-related small vessel pathology associated with intracerebral haemorrhage and cognitive impairment. Based on complementary lines of evidence from in vivo studies of individuals with hereditary, sporadic, and iatrogenic forms of cerebral amyloid angiopathy, histopathological analyses of affected brains, and experimental studies in transgenic mouse models, we present a framework and timeline for the progression of cerebral amyloid angiopathy from subclinical pathology to the clinical manifestation of the disease. Key stages that appear to evolve sequentially over two to three decades are (stage one) initial vascular amyloid deposition, (stage two) alteration of cerebrovascular physiology, (stage three) non-haemorrhagic brain injury, and (stage four) appearance of haemorrhagic brain lesions. This timeline of stages and the mechanistic processes that link them have substantial implications for identifying disease-modifying interventions for cerebral amyloid angiopathy and potentially for other cerebral small vessel diseases.
KW - Cortical superficial siderosis
KW - Transgenic mouse models
KW - Intracerebral hemorrhage
KW - Perivascular spaces
KW - Alzheimers-disease
KW - Beta
KW - Dysfunction
KW - Hereditary
KW - Microbleeds
KW - Pathology
UR - http://www.scopus.com/inward/record.url?scp=85162122185&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(23)00114-X
DO - 10.1016/S1474-4422(23)00114-X
M3 - Article
C2 - 37236210
SN - 1474-4422
VL - 22
SP - 632
EP - 642
JO - Lancet Neurology
JF - Lancet Neurology
IS - 7
ER -